eprintid: 10203878 rev_number: 9 eprint_status: archive userid: 699 dir: disk0/10/20/38/78 datestamp: 2025-01-23 12:41:30 lastmod: 2025-01-23 12:41:30 status_changed: 2025-01-23 12:41:30 type: article metadata_visibility: show sword_depositor: 699 creators_name: Rodolfi, S creators_name: Denton, CP creators_name: Ong, VH title: Systemic sclerosis-associated severe gastric antral vascular ectasia treated with tocilizumab:A case report and review of the literature ispublished: inpress divisions: UCL divisions: B02 divisions: C10 divisions: D17 divisions: G90 keywords: RNA polymerase III, Tocilizumab, gastric antral vascular ectasia, immunosuppression for gastrointestinal manifestations, systemic sclerosis note: © The Author(s) 2025. This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page. abstract: Gastric antral vascular ectasia is a frequent and potentially severe complication of systemic sclerosis. Management is presently limited to supportive care, acid suppression and endoscopic treatment. Many cases of gastric antral vascular ectasia tend to be refractory or partially responsive to standard treatment and require multiple endoscopic procedures to control the recurrent bleeding. Immunosuppression is not part of the recommended management of gastric antral vascular ectasia: limited data exist on the role of cyclophosphamide or autologous stem cell transplant in severe cases, but no prospective data or randomised controlled trial supports its routine use. Here, we present a case of an adult male patient with diffuse cutaneous systemic sclerosis complicated by arthritis and severe gastric antral vascular ectasia. The latter required multiple endoscopic procedures and remained transfusion-dependent. Due to progressive skin disease and active arthritis refractory to conventional synthetic disease-modifying antirheumatic drugs, the patient was started on tocilizumab. While he showed an early response in terms of scores related to skin involvement and arthritis, response to gastric antral vascular ectasia was unexpected. As soon as the biologic therapy was started, the patient was no longer transfusion-dependent and haemoglobin levels started to rise. Subsequent endoscopic investigations confirmed resolution of gastric antral vascular ectasia. This case is illustrative of an unexpected response to tocilizumab, and this observation is supported by the biological rationale of interleukin-6 in vascular remodelling. date: 2025-01-01 date_type: published publisher: SAGE Publications official_url: https://doi.org/10.1177/23971983241309570 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 2352864 doi: 10.1177/23971983241309570 medium: Print-Electronic pii: 10.1177_23971983241309570 lyricists_name: Denton, Christopher lyricists_name: Ong, Voon lyricists_id: CPDEN87 lyricists_id: VONGX45 actors_name: Denton, Christopher actors_id: CPDEN87 actors_role: owner full_text_status: public publication: Journal of Scleroderma and Related Disorders event_location: England issn: 2397-1983 citation: Rodolfi, S; Denton, CP; Ong, VH; (2025) Systemic sclerosis-associated severe gastric antral vascular ectasia treated with tocilizumab:A case report and review of the literature. Journal of Scleroderma and Related Disorders 10.1177/23971983241309570 <https://doi.org/10.1177/23971983241309570>. (In press). Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10203878/1/Denton_rodolfi-et-al-2025-systemic-sclerosis-associated-severe-gastric-antral-vascular-ectasia-treated-with-tocilizumab-a-case.pdf